• ImmunityBio highlighted UK patient survey findings on treatment preferences in BCG-unresponsive high-risk non-muscle-invasive bladder cancer, with results presented at ISPOR 2026 on May 17-20, 2026.
• The study found most respondents favored bladder-preserving approaches over radical cystectomy, with preferences varying by age and prior treatment experience.
• Cancer control outcomes such as recurrence risk, progression risk, and expected survival drove decision-making more than lifestyle considerations, although quality-of-life impacts remained a key trade-off for many patients.
• The findings point to a commercially relevant demand signal for bladder-sparing options, while reinforcing that uptake will depend on how individual patients weigh effectiveness against day-to-day disruption.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605220730BIZWIRE_USPR_____20260522_BW233231) on May 22, 2026, and is solely responsible for the information contained therein.